Role of osteoprotegerin and its gene polymorphisms in the occurrence of left ventricular hypertrophy in essential hypertensive patients

Medicine (United States)

Volumn 93, Issue 29, 2014, Pages e154-

  Shen, Anna ^a   Hou, Xuwei ^b   Yang, Deguang ^a   Liu, Tingrong ^a   Zheng, Dezhong ^a   Deng, Liehua ^c   Zhou, Tao ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOPROTEGERIN; ATRIAL NATRIURETIC FACTOR; SMALL INTERFERING RNA; TROPONIN I; VENTRICULAR MYOSIN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR RISK; CELL SIZE; CELL SURFACE; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; FEMALE; FIBROBLAST; GENE FREQUENCY; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; GENOTYPE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HETEROZYGOTE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RAT; UPREGULATION; ANIMAL; BLOOD; CASE CONTROL STUDY; CELL CULTURE; GENETICS; HEART VENTRICLE; HYPERTENSION; METABOLISM; MIDDLE AGED; NEWBORN; PATHOLOGY; RISK FACTOR; SPRAGUE DAWLEY RAT; STATISTICAL MODEL;

ANIMALS; ANIMALS, NEWBORN; ATRIAL NATRIURETIC FACTOR; CASE-CONTROL STUDIES; CELLS, CULTURED; FEMALE; FIBROBLASTS; GENE FREQUENCY; GENOTYPE; HEART VENTRICLES; HETEROZYGOTE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCYTES, CARDIAC; OSTEOPROTEGERIN; POLYMORPHISM, GENETIC; RATS, SPRAGUE-DAWLEY; RISK FACTORS; RNA, SMALL INTERFERING; TROPONIN I; VENTRICULAR MYOSINS;

EID: 84920851623     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000154     Document Type: Article

References (39)

1. Nielsen OW, Sajadieh A. Diagnosing left ventricular hypertrophy in arterial hypertension. BMJ. 2007;335:681-682.
2. Brady TM, Fivush B, Flynn JT, et al. Ability of blood pressure to predict left ventricular hypertrophy in children with primary hypertension. J Pediatr. 2008;152:73-788 e1.
3. Zhan S, Liu M, Yao W, et al. [Prevalence and relevant factors on echocardiographic left ventricular hypertrophy among communitybased hypertensive patients in Shanghai]. Zhonghua Liu Xing Bing Xue Za Zhi. 2002;23:182-185.
4. Mancia G, Bombelli M, Facchetti R, et al. Long-term risk of diabetes, hypertension and left ventricular hypertrophy associated with the metabolic syndrome in a general population. J Hypertens. 2008;26:1602-1611.
5. Petrovic D, Stojimirovic B. [Left ventricular hypertrophy in patients treated with regular hemodialyses.]. Med Pregl. 2008;61:369-374.
6. Kaplinsky E. Significance of left ventricular hypertrophy in cardiovascular morbidity and mortality. Cardiovasc Drugs Ther. 1994;8(Suppl 3):549-556.
7. Tovillas-Moran FJ, Vilaplana-Cosculluela M, Zabaleta-del-Olmo E, et al. Cardiovascular morbidity and mortality and electrocardiographic criteria of left ventricular hypertrophy in hypertensive patients treated in primary care. Med Clin (Barc). 2010;135:397-401.
8. Ozawa M, Tamura K, Okano Y, et al. Blood pressure variability as well as blood pressure level is important for left ventricular hypertrophy and brachial-ankle pulse wave velocity in hypertensives. Clin Exp Hypertens. 2009;31:669-679.
9. Schirmer H, Lunde P, Rasmussen K. Prevalence of left ventricular hypertrophy in a general population; The Tromso Study. Eur Heart J. 1999;20:429-438.
10. Castro MG, Rodriguez-Pascual F, Magan-Marchal N, et al. Screening of the endothelin1 gene (EDN1) in a cohort of patients with essential left ventricular hypertrophy. Ann Hum Genet. 2007;71:601-610.
11. Bella JN, Goring HH. Genetic epidemiology of left ventricular hypertrophy. Am J Cardiovasc Dis. 2012;2:267-278.
12. Arnett DK. Genetic contributions to left ventricular hypertrophy. Curr Hypertens Rep. 2000;2:50-55.
13. Kurbanova D, Eliseyeva M. Genetic background of left ventricular hypertrophy in Uzbek hypertensive men. Turk Kardiyol Dern Ars. 2010;38:466-472.
14. El-Shehaby AM, El-Khatib MM, Marzouk S, et al. Relationship of BsmI polymorphism of vitamin D receptor gene with left ventricular hypertrophy and atherosclerosis in hemodialysis patients. Scand J Clin Lab Invest. 2013;73:75-81.
15. Kaufman BD, Desai M, Reddy S, et al. Genomic profiling of left and right ventricular hypertrophy in congenital heart disease. J Card Fail. 2008;14:760-767.
16. Blazquez-Medela AM, Garcia-Ortiz L, Gomez-Marcos MA, et al. Osteoprotegerin is associated with cardiovascular risk in hypertension and/or diabetes. Eur J Clin Invest. 2012;42:548-556.
17. Noheria A, Mosley TH Jr, Kullo IJ. Association of serum osteoprotegerin with left ventricular mass in African American adults with hypertension. Am J Hypertens. 2010;23:767-774.
18. Omland T, Drazner MH, Ueland T, et al. Plasma osteoprotegerin levels in the general population: relation to indices of left ventricular structure and function. Hypertension. 2007;49:1392-1398.
19. Morinaga T, Nakagawa N, Yasuda H, et al. Cloning and characterization of the gene encoding human osteoprotegerin/osteoclastogenesis-inhibitory factor. Eur J Biochem. 1998;254:685-691.
20. Brandstrom H, Stiger F, Kahan T, et al. A single nucleotide polymorphism in the promoter region of the osteoprotegerin gene is related to intima-media thickness of the carotid artery in hypertensive patients. The Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA). Blood Press. 2004;13: 152-157.
21. Brandstrom H, Stiger F, Lind L, et al. A single nucleotide polymorphism in the promoter region of the human gene for osteoprotegerin is related to vascular morphology and function. Biochem Biophys Res Commun. 2002;293:13-17.
22. Valera ET, Brassesco MS, Scrideli CA, et al. Are patients with encephalocraniocutaneous lipomatosis at increased risk of developing low-grade gliomas? Childs Nerv Syst. 2012;28:19-22.
23. Xu HY, Hou XW, Wang LF, et al. Association between transforming growth factor beta1 polymorphisms and left ventricle hypertrophy in essential hypertensive subjects. Mol Cell Biochem. 2010;335:13-17.
24. Chen YH, Wu YW, Yang WS, et al. Relationship between bone mineral density and serum osteoprotegerin in patients with chronic heart failure. PLoS One. 2012;7:e44242.
25. Arko B, Prezelj J, Komel R, et al. Sequence variations in the osteoprotegerin gene promoter in patients with postmenopausal osteoporosis. J Clin Endocrinol Metab. 2002;87:4080-4084.
26. Langdahl BL, Carstens M, Stenkjaer L, et al. Polymorphisms in the osteoprotegerin gene are associated with osteoporotic fractures. J Bone Miner Res. 2002;17:1245-1255.
27. Castaldo C, Di Meglio F, Miraglia R, et al. Cardiac fibroblastderived extracellular matrix (biomatrix) as a model for the studies of cardiac primitive cell biological properties in normal and pathological adult human heart. Biomed Res Int. 2013;2013:352370.
28. Olesen M, Skov V, Mechta M, et al. No influence of OPG and its ligands, RANKL and TRAIL, on proliferation and regulation of the calcification process in primary human vascular smooth muscle cells. Mol Cell Endocrinol. 2012;362:149-156.
29. Su FF, Shi MQ, Guo WG, et al. High-mobility group box 1 induces calcineurin-mediated cell hypertrophy in neonatal rat ventricular myocytes. Mediators Inflamm. 2012;2012:805149.
30. Mirza M, Shaughnessy E, Hurley JK, et al. Osteopontin-c is a selective marker of breast cancer. Int J Cancer. 2008;122:889-897.
31. Kassan M, Montero MJ, Sevilla MA. Chronic treatment with pravastatin prevents early cardiovascular changes in spontaneously hypertensive rats. Br J Pharmacol. 2009;158:541-547.
32. Schoppet M, Ruppert V, Hofbauer LC, et al. TNF-related apoptosisinducing ligand and its decoy receptor osteoprotegerin in nonischemic dilated cardiomyopathy. Biochem Biophys Res Commun. 2005;338:1745-1750.
33. Liu W, Feng W, Wang F, et al. Osteoprotegerin/RANK/RANKL axis in cardiac remodeling due to immuno-inflammatory myocardial disease. Exp Mol Pathol. 2008;84:213-217.
34. Ueland T, Yndestad A, Oie E, et al. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation. 2005;111:2461-2468.
35. Garcia-Unzueta MT, Riancho JA, Zarrabeitia MT, et al. Association of the 163A/G and 1181G/C osteoprotegerin polymorphism with bone mineral density. Horm Metab Res. 2008;40:219-224.
36. Celczynska Bajew L, Horst Sikorska W, Bychowiec B, et al. The effects of osteoprotegerin (OPG) gene polymorphism in patients with ischaemic heart disease on the morphology of coronary arteries and bone mineral density. Kardiol Pol. 2011;69:573-578.
37. Choe WS, Kim HL, Han JK, et al. Association between OPG, RANK and RANKL gene polymorphisms and susceptibility to acute coronary syndrome in Korean population. J Genet. 2012;91:87-89.
38. Candido R, Toffoli B, Corallini F, et al. Human full-length osteoprotegerin induces the proliferation of rodent vascular smooth muscle cells both in vitro and in vivo. J Vasc Res. 2010;47:252-261.
39. Hou X, Hu Z, Huang X, et al. Serum osteopontin, but not OPN gene polymorphism, is associated with LVH in essential hypertensive patients. J Mol Med (Berl). 2013.